West Pharma Q1 sales $695.4M (-3%) adj EPS $1.56 (-21%), raises full-year adj EPS guidance

WEST PHARMACEUTICAL SERVICES INC

2024-Q1 EPS reported $1.55 revenue$695,400,000

Reported-diluted EPS $1.55, down 16.2% YoY; adjusted-diluted EPS $1.56, down 21.2%.
Net sales $695.4M, down 3.0% organically; Proprietary Products sales down 4.0%.
Full-year 2024 net sales guidance reaffirmed at $3.000-3.025B; adjusted EPS guidance raised to $7.63-7.88 from $7.50-7.75.
Board declares Q3 dividend $0.20/share, payable Aug 7, 2024 to holders of record Jul 31.
Repurchased 729,679 shares for $267M at avg $365.87 in Q1.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

WEST PHARMACEUTICAL SERVICES INC reported first-quarter 2024 results: revenue 695.4 million, EPS 1.55.

Period: first-quarter 2024
Revenue: 695.4 million
EPS: 1.55
Result: reported results

Exact text from the filing

Net sales of $695.4 million declined 3.0%; organic net sales also declined by 3.0%. • Reported-diluted EPS of $1.55 declined by 16.2%.

View on SEC.gov

492 earnings releases filed in the last 30 days. Browse all earnings releases →

WEST PHARMACEUTICAL SERVICES INC filing history →

Source: SEC EDGAR

accession 0000105770-24-000025

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.